Chronic obstructive pulmonary disease (COPD)

TUCOM
Dep. of Medicine
4th year
Dr. Hasan I. Sultan
25-11-2018

Chronic obstructive pulmonary disease (COPD)

Learning objectives:

1. Define COPD
2. Classify COPD
3. Recognize the risk factors for development of COPD
4. Review the pathophysiology of COPD
5. Clarify the clinical features of COPD
6. Explain the investigations of COPD
7. Discuss the management of COPD

Chronic obstructive pulmonary disease (COPD)

COPD is defined as a preventable and treatable lung disease with some significant pulmonary and extrapulmonary effects. The pulmonary component is characterised by slowly progressive airways obstruction that is not fully reversible associated with an abnormal inflammatory response of the lung to noxious particles or gases usually smoking. Extrapulmonary manifestations include impaired nutrition, weight loss and skeletal muscle dysfunction.

COPD includes:

1- **Chronic bronchitis:** cough and sputum on most days for at least 3 consecutive months for at least 2 successive years. Other causes of chronic cough should be excluded such as: asthma, pulm. TB, GERD, postnasal drip, bronchiectasis and congestive cardiac failure.

2- **Emphysema:** it is a pathological definition, define as abnormal permanent enlargement of the airspaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis, that leads to loss of elastic recoil and hyperinflation lungs.

Chronic bronchitis and emphysema are frequently found together.

Risk factors for development of COPD

1. Tobacco smoke: the most important factor (95% of patients)
2. Biomass solid fuel fires: wood, animal dung, crop residues and coal lead to high levels of indoor air pollution
3. Occupation: coal miners and those who work with silica and cadmium
4. Low birth weight, childhood infections and maternal smoking may affect growth of lung during childhood, resulting in a lower maximally attained lung function in adult life
5. Infections: recurrent infection may accelerate decline in FEV_1: persistence of adenovirus in lung tissue may alter local inflammatory response predisposing to lung damage; HIV infection is associated with emphysema
6. Low socioeconomic status
7. Cannabis smoking
8. Genetic factors: α_1-antiproteinase deficiency

Pack year: is a term used to describe the number of cigarettes a person has smoked over time. One pack year is defined as 20 manufactured cigarettes (one pack) smoked per day for one year.

Number of pack years = (number of *cigarettes* smoked per day x number of years smoked)/20 (1 pack has 20 cigarettes).

For example: a patient who has smoked 15 cigarettes a day for 40 years has a (15x40)/20 = 30 pack year smoking history.

20 pack year and more the patient under a risk of developing COPD.

Pathophysiology

- Chronic bronchitis: results in mucous glands enlargement and goblet cells hyperplasia in the epithelium of bronchial tree, leads to cough and mucus production, accompanied by neutrophilic infiltration, smooth muscle spasm and airway inflammation and fibrosis.
- Emphysema: the lung parenchyma is destroyed by action of proteolytic enzymes released by neutrophils. There are two types of emphysema, centriacinar and panacinar.
  - Centriacinar emphysema primarily involves the respiratory bronchioles, often with normal distal alveoli, is seen almost exclusively in smokers, which is the most common type.
  - Panacinar emphysema involves the entire distal lung unit, distorting and destroying alveoli and respiratory bronchioles alike; it can occur throughout the lung but may involve chiefly the lower lobes. Severe panacinar emphysema associated with α_1-antitrypsin (AAT) deficiency.

The pulmonary and systemic features of COPD.





HEALTHY BRONCHI



CHRONIC BRONCHITIS



Bronchioles continue to divide and decrease in size, becoming terminal, and then respiratory, which give the alveolar ducts, alveolar sacs and alveoli. Gas exchange begins to occur in the respiratory alveoli that bud from the respiratory bronchioles.



Histologic features of centriacinar emphysema. A section of lung tissue shows fragmented and “free-floating” alveolar septa (arrow) characteristic of emphysema

Clinical features

History: symptoms of COPD:

- Patient over the age of **40 years** present with three most common symptoms: **cough, sputum production** and **exertional dyspnea.**
- Chronic cough and sputum production are usually the first symptoms (smoker's cough), mainly in the morning, the sputum is clear (mucoid) if there is no infection. Dyspnea progresses from occurring only with extreme exertion to being present with any effort and finally to being present at rest.
- Wheezing is also common in COPD, usually with exertion, but may occur at rest in severe disease.
- Some patients with COPD lose weight and muscle mass especially in the presence of severe emphysema. Weight loss is an ominous prognostic sign in COPD.

Acute exacerbations of COPD: characterized by increased dyspnea, wheezing, cough, and sputum production. The sputum often changes in color from the usual white (mucoid) to yellow or green, sometimes with blood streaking.

Physical Findings:

- In the early stages of COPD: physical examination entirely normal.
- Signs of active smoking: an odor of smoke or nicotine staining of fingernails.
- Thin patient (significant weight loss), noncyanotic at rest and prominent use of accessory muscles of respiration occur in predominant emphysema, termed "pink puffers,"
- Normal body weight with central cyanosis visible in the lips, tongue and nail beds occur in chronic bronchitis ("blue bloaters").

Note: most patients have elements of both chronic bronchitis and emphysema and that the physical examination does not reliably differentiate the two entities.

- Patients with severe airflow obstruction may also exhibit flaring of nostrils and use of accessory muscles of respiration, sitting in the characteristic "tripod" position to facilitate the actions of the sternocleidomastoid, scalene, and intercostal muscles.
- Pursed-lip breathing: it is mean exhaling through tightly pressed (pursed lips) and inhaling through nose with mouth closed. This increase pressure in the airway lumen, prevent airways collapse and making it easier (although slower) to breath out.
- Tracheal tug: downward movement of trachea during inspiration, this indicate sever COPD, which may be due to downward displacement of mediastinum by high intrathoracic pressure generated during inspiration and by upward movement of barrel shaped chest.

- **Cricosternal distance: there is a place fit for three fingers between the cricoid cartilage and sternal notch. A reduction of this distance indicates hyperinflation of the lungs.**
- **Chest examination: Inspection: barrel chest. Palpation: decrease chest expansion bilateral. Percussion: hyperresonant bilateral. Auscultation may show diminished breath sounds, vesicular breathing sound with prolonged expiratory phase and diffuse rhonchi (high pitched, polyphonic, mainly expiratory associated with wheezes) bilateral.**

- Signs of type 2 respiratory failure and CO_2 retention: polycythemia, cyanosis, warm periphery, bounding pulses, palmar erythema and flapping tremor.
- Signs of cor pulmonale include an increased pulmonic second sound, increase jugular venous distention, hepatic congestion and hepatomegaly, and ankle edema.
- Finger clubbing is not a feature of COPD and should trigger further investigation for lung cancer, bronchiectasis or fibrosis.
- The body mass index (BMI) is of prognostic significance and should be recorded.











Evidence for increased work of breathing (supraclavicular retractions, use of accessory muscles of ventilation, and the **tripod position**, characterized by sitting with one's hands braced on the knees) is indicative of disorders of the airways (e.g., asthma, emphysema, chronic bronchitis or bronchiectasis)





Investigations

1- Pulmonary function test (Spirometry):

A- To make a diagnosis: the measurement of the FEV1 and FVC, is the "gold standard" for diagnosis of COPD. Airways obstruction (FEV1/FVC < 0.70) in a person with at least 20 pack years of tobacco exposure is a presumptive diagnosis of COPD.

B- Reversibility test: post-bronchodilator (inhaled B2-agonist) measurement of FEV1, less than 15% improvement in FEV1 occur in COPD, while in asthma more than 20%.

C- Measurement of lung volumes provides an assessment of hyperinflation: increase residual volume and total lung capacity.

D- Assess the severity of COPD depending on FEV1 results:

- Mild COPD: FEV1 ≥80% predicted
- Moderate COPD: FEV1 50–79% predicted
- Severe COPD: FEV1 30–49% predicted
- Very severe COPD: FEV1 < 30% predicted or FEV1 < 50% predicted if respiratory failure present

E- DLCO (diffusing capacity of the lung for carbon monoxide (CO)) or CO transfer factor: is markedly decreased in severe emphysema.

2- Radiologic Studies

A- Chest x-ray shows:

1- Chronic bronchitis: increase hilar shadowing (linear lines arising from the hila) with increased bronchovascular markings.

2- Emphysema: hyper inflated chest, flattened diaphragms, small vertical heart, prominent pulmonary artery, thin-walled bullae.

B- High resolution CT scan of chest: to assess the presence, distribution, and extent of emphysema, to locate the bullae before surgery or lung transplant.

3- ECG: low voltage complexes, p- pulmonale, Rt. ventricular hypertrophy.

4- FBC and ESR: to exclude anaemia or polycythaemia.

5- α1-antiproteinase: should be assayed in younger patients with predominantly basal emphysema

6- Arterial blood gases: increase in PCO2 and decrease in PO2



Spirometry. Line A (bold) represents spirometry recorded in patient with COPD. Line B (dotted) is the predicted normal spirometric curve for comparison.

Normal chest x-ray



chronic bronchitis on chest radiography are nonspecific and include increased bronchovascular markings and cardiomegaly.





Posteroanterior and lateral radiographs of the thorax in a patient with emphysema, with increased lung volume, lungs appear dark because of their increased air relative to tissue. The diaphragms appear flatter than normal. The heart is more vertical than normal and the transverse diameter of the rib cage is increased. The space between the sternum and heart and great vessels is increased on the lateral view.



High-resolution CT scan of chest of a patient with emphysema at the level of the tracheal carina. The right lung is on the left. Multiple large bullae (black holes) are evident. Many smaller areas of similar tissue destruction are also present in both lungs. The right upper lobe bronchus is seen entering the lung; its walls are thickened, suggesting chronic inflammation.

Management

A- General management:

1- Smoking cessation: Ask- Advise- Assess- Arrange.

- Complete cessation of smoking is accompanied by an improvement in lung function and deceleration in the rate of FEV1 decline. There are two principal therapy:
- Bupropion, originally developed as an antidepressant medication.
- Nicotine replacement therapy. Which is available as gum, transdermal patches, inhaler, and nasal spray.

2- Avoidance of polluted environment.

3- Pulmonary rehabilitation: encourage exercise, education, nutritional and psychological support.

4- Pneumococcal and influenza vaccination.

B- Pharmacologic treatment:

1- Mild COPD (FEV1 ≥ 80% predicted): Start on as required:

- Short-acting inhaled bronchodilators, such as the β_2-agonists salbutamol or terbutaline.
- Short-acting inhaled anticholinergic ipratropium bromide (with preference to β_2-agonists, as it reduce mucus hypersecretion as well as bronchodilation)

2- Moderate COPD (FEV1 50–79% predicted): If as required treatment do not control symptoms add

- Long acting inhaled bronchodilators β2-agonists (LABA) such as salmeterol or formoterol.
- Long acting anticholinergic tiotropium bromide.
- Combined inhaled glucocorticoid and LABA improves lung function, reduces the frequency and severity of exacerbations and improves quality of life.

3- Sever COPD (FEV1 30–49% predicted): as above plus add

- **Inhaled corticosteroids (budesonide or fluticasone) reduce the frequency and severity of exacerbations.**
- **Oral corticosteroids are useful during exacerbations only.**
- **Oral xanthins bronchodilator (Theophylline) may be used in patients who cannot use inhaled devices efficiently. It improve breathlessness and quality of life, but their use is limited by side-effects, unpredictable metabolism and drug interactions.**
- **Higher regular doses of nebulized short β2-agonists and ipratropium bromide.**
- **Oral N-acetyl cysteine has have both mucolytic and antioxidant properties.**

4- Very severe COPD (FEV1 < 30% predicted or FEV1 < 50% predicted if respiratory failure present): as above plus add

Oxygen therapy:

Long-term domiciliary oxygen therapy (LTOT) improves survival in selected patients with COPD complicated by severe hypoxaemia (arterial PaO2 less than 8.0 kPa (55 mmHg)). The patient has stopped smoking, use at least 15 hrs/day at 2–4 L/min.



Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for treatment of COPD. Post-bronchodilator FEV1 is recommended for the diagnosis and assessment of severity of COPD.

C- Surgical intervention:

- **Bullectomy: large bullae compress surrounding normal lung tissue.**
- **Lung volume reduction surgery (LVRS): to reduce hyperinflation and decrease the work of breathing.**
- **Lung transplantation: for selected patients with advanced disease.**

Acute exacerbations of COPD

Acute exacerbations of COPD: episodes of increased dyspnea and cough and change in the amount and character of sputum, with or without fever, myalgia and sore throat. Associated with deterioration in lung function and health status.

Bacterial infections (Haemophilus influenzae, Streptococcus pneumoniae, and Moraxella catarrhalis) play a role in many episodes.

Treatment:

1- Controlled oxygen at 24% or 28% should be used

2- Nebulised short-acting β2-agonists, combined with an anticholinergic agent (e.g. salbutamol and ipratropium), should be administered.

3- Oral prednisolone: reduces symptoms and improves lung function. Currently, doses of 30 mg for 10 days are recommended.

4- Antibiotics: aminopenicillin, macrolide or co-amoxiclav are recommended.

5- Non-invasive ventilation: If, despite the above measures, the patient remains tachypnoeic and acidotic ($H+ \geq 45$/$pH < 7.35$), then NIV should be commenced.

6- Invasive (conventional) mechanical ventilation: via an endotracheal tube is indicated for patients with severe respiratory distress despite initial therapy, life-threatening hypoxemia, severe hypercapnia and/or acidosis, markedly impaired mental status, respiratory arrest, hemodynamic instability, or other complications.

Thanks